Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

rly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

Prescribing information and patient product information for JANUVIA and JANUMET are attached.

JANUVIA(TM) and JANUMET(TM) are trademarks of Merck & Co., Inc. -0-

JANUVIA(TM)(sitagliptin) Tablets                     9762701


    HIGHLIGHTS OF PRESCRIBING INFORMATION


    These highlights do not include all the information needed to use

JANUVIA safely and effectively. See full prescribing information for

JANUVIA.


    JANUVIA(TM) (sitagliptin) Tablets


    Initial U.S. Approval: 2006


    INDICATIONS AND USAGE


    JANUVIA is indicated as an adjunct to diet and exercise to improve

glycemic control in patients with type 2 diabetes mellitus (type 2

diabetes). JANUVIA is indicated for:


    --  Monotherapy (1.1)


    --  Combination therapy with metformin or a peroxisome

        proliferator-activated receptor gamma (PPAR-gamma) agonist

        (e.g., thiazolidinediones) when the single agent does not

        provide adequate glycemic control. (1.2)


    Important Limitations of Use: JANUVIA should not be used in

patients with type 1 diabetes mellitus (type 1 diabetes) or for the

treatment of diabetic ketoacidosis. (1.3)


    DOSAGE AND ADMINISTRATION


    The recommended dose of JANUVIA is 100 mg once daily as

monotherapy or as combination therapy with metformin or a PPAR-gamma

agonist (e.g., thiazolidinediones). (2.1)


    JANUVIA can be taken with or without food. (2.1)



  Dosage Adjustment in Patients With Moderate, Severe and End Stage

                      Renal Disease (ESRD) (2.2)

----------------------------------------------------------------------

           50 mg once daily                   25 mg once daily

--------------------------------------------------------------------
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:8/28/2015)... The scientific team of a new biotech company ... academics in the field of aging Prof. Robert J. ... for model animals - 10 fold for nematodes) has recently ... primarily, around the stability and stress resistance of certain gene ... analysis of a model gene network links aging, stress resistance, ...
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today announced ... Logo - ... "Our new corporate identity signifies our transformation into a ... predictive analytics platform for patent claim validity." ... of the proprietary AIA Shield™ platform, the Company commenced a ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... with no dose-limiting toxicities - - ... Halozyme to seek input from regulatory authorities in order to ... into pivotal clinical program ... Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing ...
... the identification of,the gene responsible for progeria, a ... of Spanish and French researchers (Carlos,Lopez-Otin and coll. ... and coll. -,Inserm/AP-HM, Marseille, France) have successfully demonstrated ... combining two existing,pharmacological molecules, should slow down the ...
Cached Medicine Technology:Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 2Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 3Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 4Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 5Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children 2
(Date:8/28/2015)... Florida (PRWEB) , ... August 28, 2015 , ... ... holistic approach to medicine through health promotion and disease prevention, improving a patient’s ... most prevalent diseases in the community, including heart disease, cancer, diabetes, HIV/AIDS, STDs, ...
(Date:8/27/2015)... Atlanta, Georgia (PRWEB) , ... August 28, 2015 ... ... a positive impact on elementary school students’ academic performance in mathematics, according to ... in the journal Education, Finance and Policy in July, analyzed the impact of ...
(Date:8/27/2015)... BWI (PRWEB) , ... August 28, 2015 , ... Grace ... This award is added to an already impressive list of accolades for the ... was ranked as the #2 beach in the world by TripAdvisor, the world's leading ...
(Date:8/27/2015)... California (PRWEB) , ... August 27, 2015 , ... Keck ... , Seventy-seven students received their White Coats at a formal ceremony recognizing them as ... of the pharmacy profession on Saturday, August 22. Symbolizing dedication to clinical service and ...
(Date:8/27/2015)... ... ... Mesa Community College graduate, Andrew Sypher (Mesa), is one of ... leadership and engagement, to receive a Phi Theta Kappa 2015 Hites Transfer Scholarship, to ... and a $7,500 scholarship to assist in his goal of becoming a foreign diplomat ...
Breaking Medicine News(10 mins):Health News:Health Clinic Opening and Public Art Unveiling 2Health News:Four-Day School Week Can Improve Academic Performance, Study Finds 2Health News:Four-Day School Week Can Improve Academic Performance, Study Finds 3Health News:Grace Bay Beach Acknowledged as a Top Caribbean Beach for Weddings 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 3Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 4Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 2Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 3
... The American Academy of Family Physicians today announced the ... first alliance partner, The Coca-Cola Company. , (Logo: ... is a program that allows corporate partners like The ... consumers about the role their products can play in ...
... are not addressing the main differences between neighborhood food ... or reduce obesity, according to a new RAND Corporation study. ... Angeles region has no more fast-food chain establishments on a ... rather many more small food stores and other food outlets. ...
... The founders of HEAL Africa ( www.hea ... nonprofit organization that provides holistic healing including urgent care medical services ... of Congo, are conducting a seven-city tour of the U.S. to ... of war in Congo. HEAL Africa,s approach to healing conflict has ...
... ,Symphony of the Superhero, to Feature DJ Cut Chemist, Violinist ... Boychoir, Whittier Elementary Choir, The Raretones and Bells of the ... The Symphony Guild today announced ... the Superhero, an annual event which benefits Seattle ...
... in some, but effects were fleeting, scientists say , MONDAY, ... addicts beat their habit is showing some effect but is ... one-third of participants in a new study developed desired immune ... cocaine use did go down. But the effects were only ...
... ... competitive advantage , ... (PRWEB) October 5, 2009-- BodyMedia, Inc. , the pioneer in developing wearable body monitoring ... Ki Performance. Through the company,s first strategic partner in Europe, BodyMedia is extending its ...
Cached Medicine News:Health News:The American Academy of Family Physicians Launches Consumer Alliance With First Partner: The Coca-Cola Company 2Health News:The American Academy of Family Physicians Launches Consumer Alliance With First Partner: The Coca-Cola Company 3Health News:The American Academy of Family Physicians Launches Consumer Alliance With First Partner: The Coca-Cola Company 4Health News:Los Angeles fast-food restaurant ban unlikely to cut obesity, study finds 2Health News:Los Angeles fast-food restaurant ban unlikely to cut obesity, study finds 3Health News:HEAL Africa's Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 2Health News:HEAL Africa's Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 3Health News:The Symphony Guild Announces Artist Lineup for 2009 Event 2Health News:The Symphony Guild Announces Artist Lineup for 2009 Event 3Health News:Cocaine Addiction Vaccine Shows Some Success 2Health News:Cocaine Addiction Vaccine Shows Some Success 3Health News:BodyMedia, Inc. Expands Overseas Offerings and Receives Milestone Certification for Continued Global Growth 2Health News:BodyMedia, Inc. Expands Overseas Offerings and Receives Milestone Certification for Continued Global Growth 3
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs....
Medicine Products: